Virodhamine

For research use only. Not for therapeutic Use.

  • CAT Number: I042671
  • CAS Number: 287937-12-6
  • Molecular Formula: C22H37NO2
  • Molecular Weight: 347.53
  • Purity: ≥95%
Inquiry Now

Virodhamine is an endocannabinoid, it regulates neurotransmission by activating the cannabinoid (CB) receptors. Virodhamine is an antagonist of CB1 receptor and an agonist of CB2 receptor. Virodhamine induces megakaryocytic differentiation by triggering MAPK signaling and ROS production. Virodhamine can be used for the research of various neurological disorders such as Alzheimer’s and Parkinson’s diseases[1][2].
Virodhamine (50 nM; 72 h) increases adherence, membrane expansion and the size of nucleus[1].
Virodhamine (10-40 μM; 72 h) increases the expression level of CD61 and TRPV1[1].
Virodhamine (72 h) inhibits the cell proliferation of megakaryocyte cells and significantly increases the portion of high ploidy cells as compared to control[1].
Virodhamine significantly increases the protein expression level of CB2 receptorn, ROS production and NAPDH oxidase NOX4 expression in megakaryocytic cells[1].
Virodhamine (1-10 mg/kg; i.p. once) repairs the nicotine (0.8 mg/kg) and immobilization stress induced anxiety in vivo[2].


Catalog Number I042671
CAS Number 287937-12-6
Synonyms

2-aminoethyl (5Z,8Z,11Z,14Z)-icosa-5,8,11,14-tetraenoate

Molecular Formula C22H37NO2
Purity ≥95%
InChI InChI=1S/C22H37NO2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-22(24)25-21-20-23/h6-7,9-10,12-13,15-16H,2-5,8,11,14,17-21,23H2,1H3/b7-6-,10-9-,13-12-,16-15-
InChIKey DLHLOYYQQGSXCC-DOFZRALJSA-N
SMILES CCCCCC=CCC=CCC=CCC=CCCCC(=O)OCCN
Reference

[1]. Sharma DS, et al. Virodhamine, an endocannabinoid, induces megakaryocyte differentiation by regulating MAPK activity and function of mitochondria. J Cell Physiol. 2021 Feb;236(2):1445-1453.
 [Content Brief]

[2]. Hayase T. Working memory- and anxiety-related behavioral effects of repeated nicotine as a stressor: the role of cannabinoid receptors. BMC Neurosci. 2013 Feb 9;14:20.
 [Content Brief]

Request a Quote